Global Oncology Academy - Global Oncology Academy

Global Oncology Academy

Global Oncology Academy

Enhance your practice with CME
and tools that focus on the management
and treatment of patients with cancer.

Popular

Exploring Treatment Strategies in epNEC: The Emerging Role of DLL3
Exploring Treatment Strategies in epNEC: The Emerging Role of DLL3
Project Oncology®
Exploring Treatment Strategies in epNEC: The Emerging Role of DLL3
Charles Turck, PharmD, BCPS, BCCCP; Jason Starr, DO
- Charles Turck, PharmD, BCPS, BCCCP
- Jason Starr, DO
From Data to Decision: Patient Selection and Real-World Application
From Data to Decision: Patient Selection and Real-World Application
MinuteCE®
From Data to Decision: Patient Selection and Real-World Application
Christophe Le Tourneau, MD, PhD; Marc Oliva, MD, PhD
0.50 program credits
- Christophe Le Tourneau, MD, PhD
- Marc Oliva, MD, PhD
0.50 program credits
The Evidence Base: Key Trials and Emerging Data
The Evidence Base: Key Trials and Emerging Data
MinuteCE®
The Evidence Base: Key Trials and Emerging Data
Christophe Le Tourneau, MD, PhD; Marc Oliva, MD, PhD
0.50 program credits
- Christophe Le Tourneau, MD, PhD
- Marc Oliva, MD, PhD
0.50 program credits
The Case for Change: Why Perioperative Immunotherapy Matters in LA HNSCC
The Case for Change: Why Perioperative Immunotherapy Matters in LA HNSCC
MinuteCE®
The Case for Change: Why Perioperative Immunotherapy Matters in LA HNSCC
Christophe Le Tourneau, MD, PhD; Marc Oliva, MD, PhD
0.50 program credits
- Christophe Le Tourneau, MD, PhD
- Marc Oliva, MD, PhD
0.50 program credits
Building the Team: Integrating Immunotherapy Into Multidisciplinary Care
Building the Team: Integrating Immunotherapy Into Multidisciplinary Care
MinuteCE®
Building the Team: Integrating Immunotherapy Into Multidisciplinary Care
Christophe Le Tourneau, MD, PhD; Marc Oliva, MD, PhD
0.50 program credits
- Christophe Le Tourneau, MD, PhD
- Marc Oliva, MD, PhD
0.50 program credits
NEW EPISODE
From Abstract to Action in Breast Cancer: Interpreting Recent Data on Oral SERDs and Endocrine Targeting Strategies
From Abstract to Action in Breast Cancer: Interpreting Recent Data on Oral SERDs and Endocrine Targeting Strategies
MinuteCE®
From Abstract to Action in Breast Cancer: Interpreting Recent Data on Oral SERDs and Endocrine Targeting Strategies
Aditya Bardia, MD, MPH, FASCO; Erica L. Mayer, MD, MPH
0.50 program credits
- Aditya Bardia, MD, MPH, FASCO
- Erica L. Mayer, MD, MPH
0.50 program credits
NEW EPISODE
Cracking the Code: Risk Stratification Guidelines to Identify High-Risk Patients
Cracking the Code: Risk Stratification Guidelines to Identify High-Risk Patients
MinuteCE®
Cracking the Code: Risk Stratification Guidelines to Identify High-Risk Patients
Scott T. Tagawa, MD, MS; Mary-Ellen Taplin, MD
1.00 program credit
- Scott T. Tagawa, MD, MS
- Mary-Ellen Taplin, MD
1.00 program credit
Translating Evidence on TROP2-Directed ADCs Into Global Practice in Metastatic TNBC
Translating Evidence on TROP2-Directed ADCs Into Global Practice in Metastatic TNBC
MinuteCE®
Translating Evidence on TROP2-Directed ADCs Into Global Practice in Metastatic TNBC
Tiffany Traina, MD; Javier Cortes, MD, PhD
0.75 program credits
- Tiffany Traina, MD
- Javier Cortes, MD, PhD
0.75 program credits

Medical News

Medical News
131I-LNTH-1095 Plus Enzalutamide in PSMA-Avid mCRPC
07/23/2026
Read more
Medical News
Perioperative Systemic Therapy vs Surgery Alone in Colorectal Peritoneal Metastases
07/21/2026
Read more
Medical News
Talquetamab And Teclistamab Show Early Signal In Myeloma
07/20/2026
Read more
Medical News
MRI Radiomics Score And ADC Improve HCC Recurrence Prediction
07/20/2026
Read more

CME/CE

MinuteCE®
Perioperative Immunotherapy in LA-HNSCC: From Evidence to Clinical Practice
Christophe Le Tourneau, MD, PhD; Marc Oliva, MD, PhD
0.50 credits 4 episodes
- Christophe Le Tourneau, MD, PhD
- Marc Oliva, MD, PhD
0.50 credits 4 episodes
Data Meets Decision: Expert Approaches to Perioperative Immunotherapy in LA HNSCC
Data Meets Decision: Expert Approaches to Perioperative Immunotherapy in LA HNSCC
CME/CE Virtual Event
Data Meets Decision: Expert Approaches to Perioperative Immunotherapy in LA HNSCC
September 15, 2026
05:00 PM - 05:45 PM CEST
0.75 credits
What’s Next for TROP2-Directed ADCs in TNBC?
What’s Next for TROP2-Directed ADCs in TNBC?
MinuteCE®
What’s Next for TROP2-Directed ADCs in TNBC?
Tiffany Traina, MD
0.75 program credits
- Tiffany Traina, MD
0.75 program credits
Current Unmet Needs in First-Line Treatment of Metastatic TNBC
Current Unmet Needs in First-Line Treatment of Metastatic TNBC
MinuteCE®
Current Unmet Needs in First-Line Treatment of Metastatic TNBC
Javier Cortes, MD, PhD
0.75 program credits
- Javier Cortes, MD, PhD
0.75 program credits

Clinical Practice

NEW EPISODE
Precision in Practice—Bringing Targeted Therapy to mHSPC
Precision in Practice—Bringing Targeted Therapy to mHSPC
MinuteCE®
Precision in Practice—Bringing Targeted Therapy to mHSPC
Scott T. Tagawa, MD, MS; Mary-Ellen Taplin, MD
1.00 program credit
- Scott T. Tagawa, MD, MS
- Mary-Ellen Taplin, MD
1.00 program credit
NEW EPISODE
ADT Intensification in Biochemically Recurrent Prostate Cancer: When to Act
ADT Intensification in Biochemically Recurrent Prostate Cancer: When to Act
MinuteCE®
ADT Intensification in Biochemically Recurrent Prostate Cancer: When to Act
Scott T. Tagawa, MD, MS; Mary-Ellen Taplin, MD
1.00 program credit
- Scott T. Tagawa, MD, MS
- Mary-Ellen Taplin, MD
1.00 program credit
NEW EPISODE
The Power of Timing: Therapies That Change Outcomes
The Power of Timing: Therapies That Change Outcomes
MinuteCE®
The Power of Timing: Therapies That Change Outcomes
Scott T. Tagawa, MD, MS; Mary-Ellen Taplin, MD
1.00 program credit
- Scott T. Tagawa, MD, MS
- Mary-Ellen Taplin, MD
1.00 program credit
In-Person & Virtual Event
The Next Generation of Care: New Treatment Frontiers in Immunotherapy-Resistant Advanced Squamous NSCLC
September 12, 2026
Seoul

Programs

Comparing First-Line TROP2-Directed ADCs in Metastatic TNBC: Latest Clinical Evidence
Comparing First-Line TROP2-Directed ADCs in Metastatic TNBC: Latest Clinical Evidence
MinuteCE®
Comparing First-Line TROP2-Directed ADCs in Metastatic TNBC: Latest Clinical Evidence
Javier Cortes, MD, PhD
0.75 program credits
- Javier Cortes, MD, PhD
0.75 program credits
Managing Adverse Events Associated With TROP2-Directed ADCs in Metastatic TNBC
Managing Adverse Events Associated With TROP2-Directed ADCs in Metastatic TNBC
MinuteCE®
Managing Adverse Events Associated With TROP2-Directed ADCs in Metastatic TNBC
Tiffany Traina, MD
0.75 program credits
- Tiffany Traina, MD
0.75 program credits
Case Consult: First-Line Treatment in Metastatic TNBC Ineligible for Immunotherapy
Case Consult: First-Line Treatment in Metastatic TNBC Ineligible for Immunotherapy
MinuteCE®
Case Consult: First-Line Treatment in Metastatic TNBC Ineligible for Immunotherapy
Tiffany Traina, MD; Javier Cortes, MD, PhD
0.75 program credits
- Tiffany Traina, MD
- Javier Cortes, MD, PhD
0.75 program credits
Personalizing Long-Term mCSPC Treatment Decisions
Personalizing Long-Term mCSPC Treatment Decisions
Project Oncology®
Personalizing Long-Term mCSPC Treatment Decisions
Charles Turck, PharmD, BCPS, BCCCP; Bilal Siddiqui, MD
- Charles Turck, PharmD, BCPS, BCCCP
- Bilal Siddiqui, MD